NCT03575676

Efficacy and Safety of SOM3355 in Huntington's Disease Chorea

Completed Phase 2 Last updated 16 September 2019

What this trial tests

Phase 2 trial testing SOM3355 100mg BID in Huntington's Chorea in 32 participants. Completed in 22 August 2019.

Timeline

8 August 2018

Primary endpoint
22 August 2019

22 August 2019

Quick facts

Lead sponsor	SOM Innovation Biotech SA
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	32
Start date	8 August 2018
Primary completion	22 August 2019
Estimated completion	22 August 2019
Sites	4 locations across Spain

Drugs / interventions tested

• SOM3355 100mg BID — full drug profile →
• SOM3355 200mg BID — full drug profile →
• Placebo BID — full drug profile →

Conditions studied

• Huntington's Chorea — all drugs for Huntington's Chorea →

Sponsor

SOM Innovation Biotech SA — full company profile →

Who can join

18 and older, any sex, with Huntington's Chorea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase IIa study to evaluate the efficacy and safety of SOM3355 in chorea movements associated with Huntington's disease

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research.
   Jiang A, Handley RR, Lehnert K, Snell RG. · · 2023 · cited 88× · PMID 37629202 · DOI 10.3390/ijms241613021
2. Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies.
   Tong H, Yang T, Xu S, Li X, et al · · 2024 · cited 50× · PMID 38612657 · DOI 10.3390/ijms25073845
3. Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.
   Dash D, Mestre TA. · · 2020 · cited 35× · PMID 32705582 · DOI 10.1007/s13311-020-00891-w
4. Huntington's Disease Clinical Trials Corner: June 2019.
   Rodrigues FB, Ferreira JJ, Wild EJ. · · 2019 · cited 25× · PMID 31381524 · DOI 10.3233/jhd-199003
5. Paradigms and Success Stories of Natural Products in Drug Discovery Against Neurodegenerative Disorders (NDDs).
   Singh S, Chib S, Akhtar MJ, Kumar B, et al · · 2024 · cited 5× · PMID 36606589 · DOI 10.2174/1570159x21666230105110834
6. A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
   Gamez J, Calopa M, Muñoz E, Ferré A, et al · · 2023 · cited 5× · PMID 36494329 · DOI 10.1111/bcp.15635
7. Update on the Symptomatic Treatment of Huntington's Disease: From Pathophysiology to Clinical Practice.
   Olmedo-Saura G, Bernardi E, Bojtos L, Martínez-Horta S, et al · · 2025 · cited 4× · PMID 40650011 · DOI 10.3390/ijms26136220